Download Curriculum Vitae - BYU`s College of Life Sciences

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Jason Kenealey, PhD
Brigham Young University, ESC S-127 ESC, Provo, UT, 84602. 301-503-2482. [email protected].
Faculty Position
Brigham Young University, Assistant Professor, Department of Nutrition,
Dietetics and Food Science. (April 2014-present)
Research Experience
The National Eye Institute, Laboratory of S. Patricia Becerra (August 2011-April
2014)
Project Description: Deriving neuroprotective peptides from PEDF
 Identified neuroprotective PEDF peptides in cell-based
assay
 Identified putative therapeutic PEDF peptides based on
binding affinity to the neuroprotective receptor, PEDF-R
 Used biophysical techniques to characterized the binding
interface
 Established collaborations to model PEDF binding to
receptor and high-throughput screening of putative
neuroprotective peptides
 Supervised high school and undergraduate students
University of Wisconsin-Madison, Laboratory of Arthur Polans (January 2006July 2011)
Project Description: Identification of non-toxic natural products as
chemotherapeutic agents
 Identified apoptotic effect of the natural product-derived
calcium signal in cancer cells
 Demonstrated natural products elicit a unique calcium signal
using live-cell imaging
 Measured uptake of natural products into cancer cells using
live-cell imaging
 Presented data at conferences and in publications
 Contributed data and ideas for grants
Brigham Young University, Laboratory of Gerald Watt (November 2002-June
2005)
Project Description: Fe3+ release kinetics of horse spleen ferritin
 Purified ferritin from horse spleen
 Demonstrated that ferritin releases Fe3+ from through its 3fold channel.
 Determined Fe3+ release kinetics
 Identified the mechanism for Fe3+ release from ferritin
Technical Skills: Live-cell calcium imaging (both FRET and small molecule
indicators), microscopy, TUNEL staining, tissue culture (primary and cell lines),
ELISA, ligand blot, fluorescence polarization, pull-down, protein purification,
enzyme kinetics (phospholipase), protein binding, flow cytometry, SDS-PAGE
and western blotting, spectrofluorometry, cell fractionation, spectrophotometry
Software Skills: Excel, Powerpoint, Graphpad prism, Imagej, Photoshop,
Illustrator, FlowJo, Pymol
Education
B.S.
Ph.D.
Biochemistry, 2005
Minor in Business Administration
Brigham Young University
Advisor: Gerald Watt, Ph.D.
Biomolecular Chemistry, 2011
University of Wisconsin-Madison
Advisor: Arthur S. Polans, Ph.D.
Publications
Peterson J**, Oblad R**, Mecham J**, Kenealey JD. Resveratrol inhibits plasma
membrane Ca2+ ATPase inducing an increase in [Ca2+]I Under Review.
*van Ginkel PR, Yan MB, Bhattacharya S, Polans AS, Kenealey JD. Natural
products induce a G protein-mediated calcium pathway activating p53 in cancer
cells. Toxicol Appl Pharmacol. 2015 288(3):453-62.
*Kenealey JD, Subramanian P, Comitato A, Bullock J, Keehan L, Polato F,
Hoover D, Marigo V, Becerra SP. Small Retinoprotective Peptides Reveal a
Receptor-binding Region on Pigment Epithelium-derived Factor. J Biol Chem.
2015 290(42):25241-53.
*Kanavi M, Darjatmoko S, Wang S, Azari A, Farnoodian M, Kenealey JD, van
Ginkel P, Albert D, Sheibani N, Polans AS. The Sustained Delivery of
Resveratrol or a Defined Grape Powder Inhibits New Blood Vessel Formation in
a Mouse Model of Choroidal Neovascularization. 2014 Molecules. 19 (11),
17578-603.
Subramanian P, Locatelli-Hoops S, Kenealey JD, DesJardin J, Notari L, Becerra
SP. Pigment Epithelium-derived Factor (PEDF) Prevents Retinal Cell Death via
Pigment Epithelium-derived Factor-R (PEDF-R): Identification of a Functional
Ligand Binding Site. 2013. The Journal of Biological Chemistry. 288 (33): 2392842.
Kenealey JD, Colley NJ, Polans AS. Calcium in Vision. Encyclopedia of
Metalloproteins. Springer Reference, 2011.
Kenealey JD, Subramanian L, Van Ginkel PR, Darjatmoko S, Lindstrom MJ,
Ghosh SK, Song Z, Hsung RP, Kwon GS, Eliceiri KW, Albert DM, Polans AS.
Resveratrol Metabolites Do Not Elicit Early Pro-apoptotic Mechanisms in
Neuroblastoma Cells 2011. J Agric Food Chem. 59(9): 4979-86.
Johnson JL, Kenealey JD, Hilton RJ, Brosnahan D, Watt RK, Watt GD. Nonreductive iron release from horse spleen ferritin using desferoxamine chelation.
2011 Journal of Inorganic Biochemistry 105 (2): 202-207.
Subramanian L, Youssef S, Bhattacharya S, Kenealey JD, Polans AS, van
Ginkel PR. Resveratrol: challenges in translation to the clinic -- a critical
discussion. 2010 Clin Cancer Res.16(24): 5942-8.
Wilson PE, Nyborg AC, Kenealey JD, Lowery TJ, Crawford K, King CR, Engan
AJ, Johnson JL, Watt GD. Evidence for a synergistic salt-protein interaction -complex patterns of activation vs. inhibition of nitrogenase by salt. 2006.
Biophys Chem. 122(3):184-94.
*Published since coming to BYU
**BYU Undergraduates
Posters
Kenealey JD, Petersen J**, Oblad R**. Resveratrol Inhibits PMCA activity in
Breast Cancer Cells. Experimental Biology. Boston, MA, 2015.
Kenealey JD, Subramanian P, Hoover D, Becerra SP. Mapping the Receptor
Binding Site on PEDF: Implications for a Neurotrophic Role of PEDF-R. ARVO.
Seattle, WA, 2013.
Kenealey JD, Hoover D, Becerra SP. Mapping the Putative Neurotrophic
Receptor Binding Domain on Pigment Epithelium-derived Factor. 15th
International Symposium on Retinal Degeneration. Bad Goegging, Germany,
2012.
Kenealey JD, Subramanian L, Sareen D, Polans AS. Resveratrol: Discovering
Chemotherapy by Fast Chemistry. MathBio: Image Symposium. Madison, WI,
2009.
Kenealey JD, van Ginkel PR, Darjatmoko S, Polans AS. Resveratrol Modulates
Intracellular Calcium by Opening the 1,4,5 triphosphate Inositol Receptor in
Endothelial Cells. 10th meeting of the European Calcium Society. Leuven,
Belgium, 2008.
Patent
Becerra SP, Kenealey JD, Polato FP, Subramanian PP (submitted in 2014)
Novel Second-generation PEDF Related Peptides And Methods Of Uses For
Treating Ocular Conditions. Tracking number: E-157-2014/0-US-01 (US
application).
References
Dr. S. Patricia Becerra
Section Chief
National Eye Institute
301-496-6514
[email protected]
Dr. Arthur S. Polans
M.D. Matthews Professor
Departments of Ophthalmology and Visual Sciences
UW-Madison
608-265-4423
[email protected]